


A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of

AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
